Introduction: The role of postoperative radiotherapy (PORT) in the treatment of pathologic stage IIIA (N2) NSCLC remains controversial. We investigated practice patterns and outcomes for these patients in a prospectively maintained nationwide oncology outcomes database.
Methods: Patients with known histologic features of pathologic stage IIIA (N2) NSCLC who underwent an operation with negative margins and received adjuvant multiagent chemotherapy from 2004 to 2013 were identified from the National Cancer Data Base and stratified by the use of PORT. Multivariable logistic regression modeling was used to examine factors associated with receiving PORT, and multivariable proportional hazards regression was used to examine the association of treatment and mortality, adjusting for demographic, socioeconomic and clinicopathologic factors. Landmark analysis and covariate balancing propensity score (CBPS) weighting were also explored to account for immortal time bias and nonrandomization.
Results: A total of 2691 patients were identified, with a median follow-up of 32.32 months. In multivariable analysis, improved overall survival was associated with multiple factors, including younger age, female sex, lower Charlson-Deyo comorbidity index, histologic type (with squamous cell being better than adenocarcinoma), smaller tumor size, lower pathologic T stage, surgical procedure (with pneumonectomy or lobectomy being better than sublobar resection), and receipt of PORT (all p < 0.05). Before landmark analysis, the hazard ratio (HR) showed an overall survival benefit for patients receiving PORT 
Introduction
Lung cancer is the leading cause of cancer-related mortality in the world, with approximately 1.59 million deaths worldwide in 2012.
1 NSCLC accounts for 85% of all cases of lung cancer. Surgical resection remains the most successful option for cure for patients in whom NSCLC is diagnosed. 2 Although 5-year overall survival (OS) ranges from 58% to 73% for completely resected pathologic stage I disease, it decreases to less than 25% for pathologic stage III disease. 3 In this setting, randomized trials have been conducted to investigate the utility of different adjuvant treatment approaches. Adjuvant platinum-based chemotherapy has been shown to improve both local recurrence (LR) and OS in patients with pathologic node-positive disease; thus, adjuvant chemotherapy has become a standard of care in these patients. 4 Randomized data of the utility of adjuvant radiotherapy (RT) have come to conflicting conclusions. LCSG 773 included 210 patients with stage II to IIIA disease (pT3 or pN2) who had undergone surgical resection with negative margins. Patients were randomized to receive either PORT with cobalt 60 ( 60 Co) to the mediastinum to 50 Gy starting on postoperative day 28 or to observation. LR rates were improved with PORT, whereas OS remained the same. 5 The PORT Meta-Analysis included nine trials of patients treated after 1965. This analysis suggested that OS was worse for patients who received PORT. Subset analysis showed a detriment in resected stage I to II patients, but no adverse effect in pN2 disease. However, there are a few key criticisms of this study. First, 25% of patients included had stage T1N0 disease. Second, the RT technique is no longer used; specifically, 60 Co machines were used with large field sizes, which carried the risk of worse pulmonary and cardiac toxicities than would be seen with modern techniques. Third, some argue that some of the trials included were poorly designed (for example, few of the included trials were able to include the cause of death, whether from malignancy or treatment-related toxicity). 6 A reanalysis of the ANITA trial suggested results different from those of the aforementioned two studies. The ANITA trial included patients with stage IB to IIIA NSCLC treated with surgery who were randomized to either adjuvant cisplatin/vinorelbine chemotherapy or observation. The reanalysis looked at the impact of PORT. Overall, PORT was detrimental to survival. However, for pN2 disease treated either with or without adjuvant chemotherapy, PORT improved survival. 7 Retrospective evidence has also come to differing conclusions. In an analysis of more than 6000 nodepositive patients from the Surveillance, Epidemiology and End Results (SEER) database who were treated from 1983 to 1998, the authors noted that mortality due to heart disease was independently associated with PORT, with the overall detriment to OS disappearing by 1989, presumably as modern radiation treatment techniques came into use. 8 In another analysis of the SEER database that included more than 7000 patients treated from 1998 to 2002, the use of modern PORT was associated with a decreased OS in patients with pN0 and pN1 disease but an improved OS for patients with pN2 disease. 9 In a review of retrospective studies that excluded patients treated with 60 Co machines and included patients treated with modern linear accelerator technology, Patel et. al found that for patients with pN2 disease PORT had an OS and LR benefit compared with for patients who did not receive PORT. 10 The 2016 update of the American National Comprehensive Cancer Network guidelines for NSCLC recommend adjuvant RT for pN2 disease with negative margins. 11 A 2015 American Society for Radiation Oncology executive summary of evidence-based clinical practice guidelines noted that high-level evidence suggested that PORT improves local control for patients with N2 disease. 12 On the other hand, the 2015 update of the European Society for Medical Oncology guidelines for pathologic stage IIIA (N2) NSCLC noted that in cases of complete resection (that is, resection to negative margins), the addition of postoperative RT is not routinely recommended. 13 In the setting of this conflicting data and international recommendations, we thought it was appropriate to query a large national database as we await results from contemporary clinical trials investigating the utility of PORT for patients with pN2 disease. 14 The National Cancer Data Base (NCDB) is a joint project of the American College of Surgeons and the American Cancer Society that draws data from more than 1500 accredited cancer programs accounting for 70% of all newly diagnosed cancer cases in the United States. It also allowed us to capture a modern cohort of patients who were treated from 2004 to 2013 and thus were most likely treated with modern chemotherapy and modern RT techniques. The NCDB carries some advantages over the SEER database, as the NCDB includes data on younger patients, pathologic factors, chemotherapy use, RT techniques and doses, and medical comorbidities, which were included in our analysis. Another advantage of national database studies is that they include a very large number of patients treated in different practice settings-indeed, more patients than could ever be included in a randomized clinical trial.
Methods
Patients with pathologic stage IIIA (pN2) NSCLC diagnosed from 2004 to 2013 were identified from the NCDB. Patients who underwent surgery with negative margins and received adjuvant multiagent chemotherapy were identified and stratified by the use of PORT. Adjuvant chemotherapy was defined as chemotherapy initiated within 180 days from surgery. To prevent receipt of concurrent chemoradiation, patients in the PORT group were required to have received radiation 98 days or more past the day of chemotherapy initiation. Because this requirement lent a survival advantage to the PORT group, patients in the non-PORT group were required to have survived at least 98 days past the day of chemotherapy initiation. A CONSORT diagram describes the inclusion and exclusion criteria in detail (Fig. 1 ). A landmark time was then set at 120 days after the initiation date of adjuvant chemotherapy to prevent survival bias in the PORT group, as this was the median time to initiation of PORT.
Patient demographic, socioeconomic, and clinicopathologic factors were compared between the PORT and non-PORT groups using chi-square and Fisher's exact tests and independent sample t tests and Wilcoxon rank sum tests for categorical and continuous factors, respectively. Multivariable logistic regression was used to determine independent factors for receipt of PORT, constructed from all factors significant at the 0.20 a level from univariable modeling. The primary outcome was OS, defined as the months from diagnosis until death or last follow-up. Patients who did not die were censored in the analysis. The Kaplan-Meier method was used with a log-rank test to compare survival between the PORT and non-PORT groups. Multivariable Cox proportional hazards regression was used to assess independent contributors to OS, including PORT receipt, constructed from all factors significant at the 0.20 a level from univariable modeling in addition to any remaining factors from the final logistic model predicting PORT receipt. Subsequently, the independent contribution to OS by PORT receipt was analyzed by implementing covariate balancing propensity score (CBPS) weighting. An adjusted Kaplan-Meier method was used, as was a weighted univariable Cox proportional hazards regression. A landmark analysis was then performed for all patients who survived at least 120 days after initiation of chemotherapy. Patients were considered to be in the PORT group if they had received PORT at this 120-day landmark; otherwise, they were considered to be in the non-PORT group. The Kaplan-Meier method was again used with a log-rank test to compare survival (from landmark time) between groups, and a multivariable Cox proportional hazards model was constructed from the same factors as the nonlandmark model to assess whether PORT still had the same independent effect on survival. Then, instead of model adjustment, the independent effect of treatment group on survival was again *Adjuvant chemotherapy was defined as chemotherapy iniƟated within 180 days from surgery n represents paƟents excluded, N represents paƟents leŌ analyzed by implementing CBPS weights. An adjusted Kaplan-Meier method was used along with a weighted univariable Cox proportional hazards regression to compare survival between the landmark treatment groups after weighting. All p values were two sided with statistical significance evaluated at the 0.05 a level. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.2.4 for Windows XP, 64-bit version.
Results
A total of 2691 patients were identified, with a median time to death or last follow-up of 32.23 months (range 4.37-126.95). Patient demographic and clinical characteristics for the PORT and non-PORT groups are compared in Table 1 .
On univariable analysis, facility type, facility location, age, sex, ethnicity, Charlson-Deyo comorbidity index, tumor size, clinical stage, pathologic T stage, surgical procedure, and receipt of PORT were significant predictors for OS at the 0.20 a level. Primary payer status, laterality, histologic type, and grade were not significant predictors for OS. On multivariable analysis, improved survival was associated with multiple factors, including younger age, female sex, lower Charlson-Deyo comorbidity index, histologic type (with squamous cell being better than adenocarcinoma), smaller tumor size, lower pathologic T stage, surgical procedure (with lobectomy and pneumonectomy both being better than sublobar resection), and receipt of PORT. These findings are summarized in Table 2 Table 3 .
Discussion
Our updated analysis of the NCDB from 2004 to 2013 suggests that PORT is associated with improved survival for patients with pN2 NSCLC treated with complete resection and adjuvant multiagent chemotherapy.
Our results are not in accord with those of the older LCSG trial. This is presumably due to patients being treated with older techniques that increased their risk for development of cardiac and pulmonary toxicity. 5 This also explains why our results disagree with those of the PORT Meta-Analysis. 6 The more modern ANITA trial included patients treated with more modern radiation techniques, which might explain why on subset analysis, that trial found a survival benefit for patients with pN2 disease treated with PORT. 7 Of note, the SEER work of Lally et. al examined how PORT has become safer as modern techniques have come into use, also helping to explain why our cohort of patients from 2004 to 2013 with pN2 disease had an OS benefit from PORT. 8 As noted earlier, the American National Comprehensive Cancer Network guidelines recommend PORT for patients with pN2 disease; however, only 19% of a modern cohort of patients received PORT.
At least a few other analyses agree with our results. Corso et al. analyzed 30,552 patients in the NCDB from 1998 to 2006 with stage II to IIIA NSCLC treated with surgery to negative margins with or without PORT. Five-year OS was improved for patients with N2 disease who received PORT (27.8% versus 34.1%, p < 0.001). 15 Our analysis differs from theirs in that we include a more contemporary cohort, and thus patients who were more likely to have been treated with modern techniques. 3. We also specifically included only patients treated with multiagent chemotherapy, whereas Corso et. al included patients treated either with or without chemotherapy. 16 Mikell et al. included only patients treated with adjuvant chemotherapy; however, they did not exclude patients treated with single-agent chemotherapy.
Our conclusion that PORT was beneficial in the NCDB was also noted in a prior study by Robinson et al. They noted a hazard ratio of 0.886 (95% CI: 0.798-0.988), favoring the use of PORT. In their series, the median survival for PORT compared with no PORT was 45.2 months versus 40.7 months, respectively, with a median follow-up of 22.0 months (range 0-72 months). 17 Our study population differed from their study in that we included only patients treated with multiagent chemotherapy and only patients treated with sequential chemotherapy followed by radiation in the PORT group. Also, our data are based on an updated release of the NCDB, which included histologic information and allowed us to limit the analysis to only patients with known histologic types of NSCLC and investigate the impact this might have on receipt of PORT and OS. Our analytical methods differed from those in their study in that we performed CBPS weighting, a landmark analysis, and both in parallel to mitigate immortal time bias and to improve the efficiency of adjustment by balancing groups on known covariates. Robinson et. al note a few other possible reasons why both of our analyses disagree with older randomized data: treatment volumes were larger in the older studies, the accuracy of computed tomography-based treatment planning was not available, and the dose per fraction sizes was higher than current standards. 17 A recent meta-analysis of PORT trials comparing 60 Co-and linear accelerator-based treatment found an OS benefit for PORT versus observation only when radiation was delivered by a linear accelerator. 16 Retrospective series have noted improvements in outcomes with PORT with reduced treatment volumes, modern treatment techniques, doses less than 54 Gy, and a standard dose of 2 Gy or less per fraction. [18] [19] [20] [21] [22] There are some inherent limitations to the use of the NCDB in our study. As it is an observational study, the patients were not randomized. Because of this, we ultimately could not control for all possible covariates; however, we attempted to mitigate the problem by implementing CBPS weighting to balance the distribution of known covariates between treatment groups. 21 On multivariable analysis, there were certain factors associated with receipt of PORT (i.e., facility type, facility location, lower Charlson-Deyo comorbidity index, and higher grade). This has the potential to create bias that would not exist in a randomized control trial. An inevitable side effect of nonrandomization is the possible presence of immortal time bias. That is, patients in the PORT group may exhibit biased improved survival because they lived longer to receive PORT. We attempted to mitigate this problem with a landmark analysis, but all landmark analyses are limited by the arbitrary selection of landmark time and the exclusion of events preceding the landmark time. We chose 120 days after initiation of chemotherapy as a reasonable landmark time. We determined that only 2% of events were excluded for the landmark analysis. We carried out survival analyses from this landmark time and grouped patients in the PORT group only if they had received PORT by the landmark time. Local control and cause-specific survival were not reported, although one might assume that the vast majority of deaths in this population would be caused by lung cancer; thus, the cause-specific survival and OS would be very similar. We also attempted to adjust for this limitation with the Charlson comorbidity index. Because it is reasonable that healthier patients receive PORT, we adjusted for Charlson comorbidity index, histologic type, grade, size of tumor, AJCC clinical stage, and AJCC pathologic stage in multivariable modeling to find the independent effect of PORT on OS, regardless of these factors. Additionally, CBPS weighting balanced the distribution of these factors and others between the two groups. The weighting performed well and served as another way to look at the independent effect of PORT on OS despite these factors. Although we were able to exclude patients who did not receive multiagent chemotherapy, data on chemotherapy agents or the number of cycles are not included in the database.
Evidence from new randomized trials should better delineate the role of PORT in this patient population on which contemporary radiation techniques have been used. We eagerly anticipate the results of the LungART trial, the estimated study completion date of which is February 2022. This trial is enrolling patients with completely resected pN2 NSCLC and randomizing them to no PORT or conformal mediastinal PORT with 54 Gy delivered in 27 to 30 fractions, with the primary end point being disease-free survival.
14 Our study design has some similarities to that of the LungART trial. Our study population was treated to a similar dose by excluding patients treated with less than 45 Gy. We included a modern cohort of patients who were most likely treated with contemporary techniques, and the LungART protocol designates that patients be treated with contemporary techniques with mandatory quality assurance procedures. We excluded patients treated with concurrent chemoradiation, which is an exclusion criteria in LungART as well. We hope that this trial provides definitive guidance as to the role of PORT for patients with stage IIIA (pN2).
